Latest News and Press Releases
Want to stay updated on the latest news?
-
REDWOOD CITY, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics,...
-
REDWOOD CITY, Calif., Jan. 08, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
-
REDWOOD CITY, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc., (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
-
$70 Million Safety and $2.5 Million Clinical Candidate Designation Milestones Achieved Enters 2016 with $227 Million in Pro-Forma Cash REDWOOD CITY, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) --...
-
REDWOOD CITY, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and...
-
REDWOOD CITY, Calif., Dec. 11, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) presented new data related to the development of a novel predictive biomarker for vantictumab...
-
REDWOOD CITY, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and...
-
REDWOOD CITY, Calif., Nov. 09, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) presented clinical and preclinical data related to three of its clinical-stage programs at the...
-
NATIONAL HARBOR, Md. and REDWOOD CITY, Calif., Nov. 07, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and...
-
REDWOOD CITY, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel cancer stem cell (CSC) and immuno-oncology...